These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 11424634

  • 1. Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life.
    Bethoux F, Miller DM, Kinkel RP.
    Mult Scler; 2001 Apr; 7(2):137-42. PubMed ID: 11424634
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
    Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B.
    Eur J Neurol; 2008 Mar; 15(3):284-8. PubMed ID: 18290849
    [Abstract] [Full Text] [Related]

  • 3. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 4. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
    Nos C, Sastre-Garriga J, Borràs C, Río J, Tintoré M, Montalban X.
    Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 7. Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
    Hoogervorst EL, Kalkers NF, van Winsen LML, Uitdehaag BM, Polman CH.
    Mult Scler; 2001 Oct; 7(5):335-9. PubMed ID: 11724450
    [Abstract] [Full Text] [Related]

  • 8. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S, Cagiran I, Ormeci B, Idiman E.
    J Neurol Sci; 2004 Mar 15; 218(1-2):3-7. PubMed ID: 14759626
    [Abstract] [Full Text] [Related]

  • 9. [Change of interleukin-4 and interleukin-12 levels after therapy of multiple sclerosis relapse with methylprednisolone].
    Bartosik-Psujek H, Magryś A, Montewka-Kozioł M, Stelmasiak Z.
    Neurol Neurochir Pol; 2005 Mar 15; 39(3):207-12. PubMed ID: 15981158
    [Abstract] [Full Text] [Related]

  • 10. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
    Pascual AM, Boscá I, Escutia M, Bernat A, Coret F, Casanova B.
    Neurologia; 2008 Mar 15; 23(2):73-7. PubMed ID: 17641984
    [Abstract] [Full Text] [Related]

  • 11. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
    Martinelli V, Rocca MA, Annovazzi P, Pulizzi A, Rodegher M, Martinelli Boneschi F, Scotti R, Falini A, Sormani MP, Comi G, Filippi M.
    Neurology; 2009 Dec 01; 73(22):1842-8. PubMed ID: 19949030
    [Abstract] [Full Text] [Related]

  • 12. [Effect of methylprednisolone on emotional functioning of patients with multiple sclerosis].
    Kułakowska A, Drozdowski W, Halicka D, Kochanowicz J, Braszko JJ.
    Pol Merkur Lekarski; 2002 Sep 01; 13(75):200-3. PubMed ID: 12474570
    [Abstract] [Full Text] [Related]

  • 13. Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability.
    Ayache SS, Créange A, Farhat WH, Zouari HG, Mylius V, Ahdab R, Abdellaoui M, Lefaucheur JP.
    Eur J Neurol; 2014 Apr 01; 21(4):630-6. PubMed ID: 24471453
    [Abstract] [Full Text] [Related]

  • 14. Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
    Li XL, Zhang ZC, Zhang B, Jiang H, Yu CM, Zhang WJ, Yan X, Wang MX.
    Int Immunopharmacol; 2014 Dec 01; 23(2):546-9. PubMed ID: 25448497
    [Abstract] [Full Text] [Related]

  • 15. Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
    Hervás-García JV, Ramió-Torrentà L, Brieva-Ruiz L, Batllé-Nadal J, Moral E, Blanco Y, Cano-Orgaz A, Presas-Rodríguez S, Torres F, Capellades J, Ramo-Tello C.
    Eur J Neurol; 2019 Mar 01; 26(3):525-532. PubMed ID: 30351511
    [Abstract] [Full Text] [Related]

  • 16. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
    Byrne S, Mason D.
    N Z Med J; 2012 Feb 24; 125(1350):37-44. PubMed ID: 22382255
    [Abstract] [Full Text] [Related]

  • 17. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE.
    Mult Scler; 2011 Aug 24; 17(8):970-9. PubMed ID: 21421809
    [Abstract] [Full Text] [Related]

  • 18. Importance of an individual's evaluation of functional status for health-related quality of life in patients with multiple sclerosis.
    Gavelova M, Nagyova I, Rosenberger J, Krokavcova M, Gdovinova Z, Groothoff JW, van Dijk JP.
    Disabil Health J; 2015 Jul 24; 8(3):372-9. PubMed ID: 25981341
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.
    Najmi Varzaneh F, Najmi Varzaneh F, Azimi AR, Rezaei N, Sahraian MA.
    Acta Neurol Belg; 2014 Dec 24; 114(4):273-8. PubMed ID: 24604685
    [Abstract] [Full Text] [Related]

  • 20. CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
    Szczuciński A, Kalinowska A, Losy J.
    Eur Neurol; 2007 Dec 24; 58(4):228-32. PubMed ID: 17827967
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.